Real-Life Data of Chronic Hepatitis C Patients Treated with Direct-Acting Oral Antivirals: A Single-Center Study

Abstract

(P)/ritonavir (R)/dasabuvir and OBV/P/R/ribavirin in 76.5% (n=39) appears to be used. A statistically significant difference was found between the alanine aminotransferase, aspartate aminotransferase measurements, and platelet counts of the subjects participating in the study at the beginning, at the 4 th week, at the end of the treatment, and at the 12 th week (p=0.001). In these cases, a sustained virological response was achieved in 100%. In the follow-up of the cases, no serious side effects that required drug discontinuation were observed. Conclusion: Our study showed that the treatment success of DAAs is 100% and their side-effect profiles are good.